Evidence map›Paper›PMID 38360050›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024

Molecular Imaging of Acute Graft-Versus-Host Disease.

Chiara Bernardi, Valentina Garibotto, Behnaz Mobashwera, Robert S Negrin, Israt S Alam, Federico Simonetta

Open access · hybridAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Radiology. Imaging cancer · 2025
    Trial
  2. Article
  3. Review
  4. Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Chiara BernardiDivision of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Valentina GaribottoTranslational Research Center for Oncohematology, Department of Medicine, University of Geneva, Geneva, Switzerland.
Behnaz MobashweraDepartment of Hematology, Southampton General Hospital, University Hospital Southampton, Southampton, United Kingdom.
Robert S NegrinDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, California; and.
Israt S AlamMolecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, California federico.simonetta@unige.ch israt@stanford.edu.
Federico SimonettaDivision of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland; federico.simonetta@unige.ch israt@stanford.edu.
Stanford University · USCentre d'Imagerie BioMedicale · CHSouthampton General Hospital · GBUniversity Hospital of Geneva · CHUniversity of Geneva · CH

Funding

Developing clinically relevant PET tracers to image T cell activation for improved cancer immunotherapy monitoringR01CA286998 · NCI · STANFORD UNIVERSITY · PI Michelle Louise James · 2024 to 2026
$1.7M
NCI NIH HHS R01 CA286998
6 · The paper itself

Abstract

Noninvasive molecular imaging of acute graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation has great potential to detect GvHD at the early stages, aid in grading of the disease, monitor treatment response, and guide therapeutic decisions. Although the specificity of currently available tracers appears insufficient for clinical GvHD diagnosis, recently, several preclinical studies have identified promising new imaging agents targeting one or more biologic processes involved in GvHD pathogenesis, ranging from T-cell activation to tissue damage. In this review, we summarize the different approaches reported to date for noninvasive detection of GvHD using molecular imaging with a specific focus on the use of PET. We discuss possible applications of molecular imaging for the detection of GvHD in the clinical setting, as well as some of the predictable challenges that are faced during clinical translation of these approaches.

Indexed as

clinicalgraft-versus-host diseasehematologymolecular imagingPET/CTpreclinical

Identifiers

PMID38360050
PMCPMC10924161
OpenAlexW4391839536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.